Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 385

1.

A phase II study of extended low-dose temozolomide in recurrent malignant gliomas.

Khan RB, Raizer JJ, Malkin MG, Bazylewicz KA, Abrey LE.

Neuro Oncol. 2002 Jan;4(1):39-43.

2.

Temozolomide chemotherapy of patients with recurrent anaplastic astrocytomas and glioblastomas.

Sipos L, Vitanovics D, Afra D.

Ideggyogy Sz. 2004 Nov 20;57(11-12):394-9.

PMID:
15662767
3.

Temozolomide in radio-chemotherapy combined treatment for newly-diagnosed glioblastoma multiforme: phase II clinical trial.

Lanzetta G, Campanella C, Rozzi A, Nappa M, Costa A, Fedele F, Innocenzi G, Gagliardi FM, Salvati M, Minniti G, Frati A, Frati L, Vecchione A.

Anticancer Res. 2003 Nov-Dec;23(6D):5159-64.

PMID:
14981983
4.

A first feasibility study of temozolomide for Japanese patients with recurrent anaplastic astrocytoma and glioblastoma multiforme.

Aoki T, Mizutani T, Ishikawa M, Sugiyama K, Hashimoto N.

Int J Clin Oncol. 2003 Oct;8(5):301-4.

PMID:
14586755
5.
6.

Multicenter phase II trial of temozolomide in patients with glioblastoma multiforme at first relapse.

Brada M, Hoang-Xuan K, Rampling R, Dietrich PY, Dirix LY, Macdonald D, Heimans JJ, Zonnenberg BA, Bravo-Marques JM, Henriksson R, Stupp R, Yue N, Bruner J, Dugan M, Rao S, Zaknoen S.

Ann Oncol. 2001 Feb;12(2):259-66.

PMID:
11300335
7.

Temozolomide as a second-line systemic regimen in recurrent high-grade glioma: a phase II study.

Brandes AA, Ermani M, Basso U, AmistĂ  P, Berti F, Scienza R, Rotilio A, Pinna G, Gardiman M, Monfardini S.

Ann Oncol. 2001 Feb;12(2):255-7.

PMID:
11300334
8.

Temozolomide for recurrent low-grade spinal cord gliomas in adults.

Chamberlain MC.

Cancer. 2008 Sep 1;113(5):1019-24. doi: 10.1002/cncr.23677.

9.

Safety and efficacy of temozolomide in patients with recurrent anaplastic oligodendrogliomas after standard radiotherapy and chemotherapy.

Chinot OL, Honore S, Dufour H, Barrie M, Figarella-Branger D, Muracciole X, Braguer D, Martin PM, Grisoli F.

J Clin Oncol. 2001 May 1;19(9):2449-55.

PMID:
11331324
10.

Multi-institutional phase II study of temozolomide administered twice daily in the treatment of recurrent high-grade gliomas.

Balmaceda C, Peereboom D, Pannullo S, Cheung YK, Fisher PG, Alavi J, Sisti M, Chen J, Fine RL.

Cancer. 2008 Mar 1;112(5):1139-46. doi: 10.1002/cncr.23167.

11.

Phase I study of temozolomide and escalating doses of oral etoposide for adults with recurrent malignant glioma.

Korones DN, Benita-Weiss M, Coyle TE, Mechtler L, Bushunow P, Evans B, Reardon DA, Quinn JA, Friedman H.

Cancer. 2003 Apr 15;97(8):1963-8.

12.

Phase II study of protracted daily temozolomide for low-grade gliomas in adults.

Kesari S, Schiff D, Drappatz J, LaFrankie D, Doherty L, Macklin EA, Muzikansky A, Santagata S, Ligon KL, Norden AD, Ciampa A, Bradshaw J, Levy B, Radakovic G, Ramakrishna N, Black PM, Wen PY.

Clin Cancer Res. 2009 Jan 1;15(1):330-7. doi: 10.1158/1078-0432.CCR-08-0888.

13.

A multicenter cohort study of dose-dense temozolomide (21 of 28 days) for the treatment of recurrent anaplastic astrocytoma or oligoastrocytoma.

Neyns B, Chaskis C, Joosens E, Menten J, D'Hondt L, Branle F, Sadones J, Michotte A.

Cancer Invest. 2008 Apr-May;26(3):269-77. doi: 10.1080/07357900701708393.

PMID:
18317968
14.

Temozolomide chemotherapy in patients with recurrent malignant gliomas.

Yang SH, Kim MK, Lee TK, Lee KS, Jeun SS, Park CK, Kang JK, Kim MC, Hong YK.

J Korean Med Sci. 2006 Aug;21(4):739-44.

15.

Phase I trial of temozolomide using an extended continuous oral schedule.

Brock CS, Newlands ES, Wedge SR, Bower M, Evans H, Colquhoun I, Roddie M, Glaser M, Brampton MH, Rustin GJ.

Cancer Res. 1998 Oct 1;58(19):4363-7.

16.

Temozolomide and oral VP-16 for children and young adults with recurrent or treatment-induced malignant gliomas.

Korones DN, Smith A, Foreman N, Bouffet E.

Pediatr Blood Cancer. 2006 Jul;47(1):37-41.

PMID:
16047359
17.

Phase II study of neoadjuvant 1, 3-bis (2-chloroethyl)-1-nitrosourea and temozolomide for newly diagnosed anaplastic glioma: a North American Brain Tumor Consortium Trial.

Chang SM, Prados MD, Yung WK, Fine H, Junck L, Greenberg H, Robins HI, Mehta M, Fink KL, Jaeckle KA, Kuhn J, Hess K, Schold C.

Cancer. 2004 Apr 15;100(8):1712-6.

18.

Phase II evaluation of temozolomide and 13-cis-retinoic acid for the treatment of recurrent and progressive malignant glioma: a North American Brain Tumor Consortium study.

Jaeckle KA, Hess KR, Yung WK, Greenberg H, Fine H, Schiff D, Pollack IF, Kuhn J, Fink K, Mehta M, Cloughesy T, Nicholas MK, Chang S, Prados M; North American Brain Tumor Consortium.

J Clin Oncol. 2003 Jun 15;21(12):2305-11.

PMID:
12805331
19.

[Favourable result for temozolomide in recurrent high-grade glioma].

Taal W, van der Rijt CD, Sillevis Smitt PA, Kros JM, van Heuvel I, Enting RH, van den Bent MJ.

Ned Tijdschr Geneeskd. 2005 Jun 18;149(25):1393-9. Dutch.

PMID:
15997692
20.

Phase II trial of continuous dose-intense temozolomide in recurrent malignant glioma: RESCUE study.

Perry JR, BĂ©langer K, Mason WP, Fulton D, Kavan P, Easaw J, Shields C, Kirby S, Macdonald DR, Eisenstat DD, Thiessen B, Forsyth P, Pouliot JF.

J Clin Oncol. 2010 Apr 20;28(12):2051-7. doi: 10.1200/JCO.2009.26.5520. Epub 2010 Mar 22. Erratum in: J Clin Oncol. 2010 Jul 20;28(21):3543.

PMID:
20308655

Supplemental Content

Support Center